| 6FZU: reference: Optimizing a weakly binding fragment into a potent RORgammat inverse agonist with efficacy in an in vivo inflammation model., Carcache D, Vulpetti A, Kallen J, Mattes H, Orain D, Stringer R, Vangrevelinghe E, Wolf RM, Kaupmann K, Ottl J, Dawson King J, Cooke NG, Hoegenauer K, Billich A, Wagner J, Guntermann C, Hintermann S, J Med Chem. 2018 Jul 10. doi: 10.1021/acs.jmedchem.8b00529. PMID: 29990434 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).